Collectively, these findings strongly suggest that the combination of osimertinib and leelamine is a promising therapeutic approach for EGFR-mutant cancers, particularly those with the challenging C797S mutation, which confers resistance to osimertinib. This evidence concerns the gene EGFR and cancer.